IL235284A0 - Methods for the treatment and prevention of Staphylococcus aureus infections and related conditions - Google Patents

Methods for the treatment and prevention of Staphylococcus aureus infections and related conditions

Info

Publication number
IL235284A0
IL235284A0 IL235284A IL23528414A IL235284A0 IL 235284 A0 IL235284 A0 IL 235284A0 IL 235284 A IL235284 A IL 235284A IL 23528414 A IL23528414 A IL 23528414A IL 235284 A0 IL235284 A0 IL 235284A0
Authority
IL
Israel
Prior art keywords
treating
methods
staphylococcus aureus
associated conditions
aureus infections
Prior art date
Application number
IL235284A
Other languages
English (en)
Hebrew (he)
Inventor
J Torres Victor
Ashley L Dumont
Original Assignee
Univ New York
J Torres Victor
Ashley L Dumont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York, J Torres Victor, Ashley L Dumont filed Critical Univ New York
Publication of IL235284A0 publication Critical patent/IL235284A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
IL235284A 2012-05-02 2014-10-22 Methods for the treatment and prevention of Staphylococcus aureus infections and related conditions IL235284A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641543P 2012-05-02 2012-05-02
PCT/US2013/032436 WO2013165613A1 (en) 2012-05-02 2013-03-15 Methods of treating and preventing staphylococcus aureus infections and associated conditions

Publications (1)

Publication Number Publication Date
IL235284A0 true IL235284A0 (en) 2014-12-31

Family

ID=49514732

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235284A IL235284A0 (en) 2012-05-02 2014-10-22 Methods for the treatment and prevention of Staphylococcus aureus infections and related conditions

Country Status (9)

Country Link
US (1) US9657103B2 (enExample)
EP (1) EP2844287A4 (enExample)
JP (1) JP2015517463A (enExample)
CN (1) CN104428000A (enExample)
AU (1) AU2013257161B2 (enExample)
CA (1) CA2871152A1 (enExample)
HK (1) HK1207981A1 (enExample)
IL (1) IL235284A0 (enExample)
WO (1) WO2013165613A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014270598B2 (en) * 2013-05-21 2018-09-20 Arsanis Biosciences Gmbh Generation of highly potent antibodies neutralizing the LukGH (LukAB) toxin of Staphylococcus aureus
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
CN108135961A (zh) * 2015-06-12 2018-06-08 台湾基督长老教会马偕医疗财团法人马偕纪念医院 调控免疫反应的方法及多肽
CN110913883A (zh) * 2017-06-13 2020-03-24 综合生物治疗疫苗公司 包含金黄色葡萄球菌杀白细胞素luka和lukb来源的多肽的免疫原性组合物
US12291562B2 (en) 2019-04-01 2025-05-06 Rush University Medical Center Reagents and assays using modified integrin domains
CN114437187B (zh) * 2022-02-09 2023-06-20 淮北师范大学 一种细菌素Bacin A4及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
GB8901778D0 (en) 1989-01-27 1989-03-15 Univ Court Of The University O Manipulatory technique
US5602299A (en) 1992-09-23 1997-02-11 Mount Sinai School Of Medicine Of The City University Of New York Transgenic animal models for neurodegenerative disease
JPH07132033A (ja) 1993-11-12 1995-05-23 Hoechst Japan Ltd アルツハイマー病モデルトランスジェニック動物
US6066778A (en) 1996-11-06 2000-05-23 The Regents Of The University Of Michigan Transgenic mice expressing APC resistant factor V
US20030162956A1 (en) * 1997-04-07 2003-08-28 Human Genome Sciences, Inc. Leukocyte regulatory factors 1 and 2
JP2004504827A (ja) * 2000-07-31 2004-02-19 ザ　ジェネラル　ホスピタル　コーポレーション 高親和性インテグリンポリペプチドおよびその使用方法
US7323552B2 (en) * 2000-07-31 2008-01-29 The General Hospital Corporation Variant integrin polypeptides and uses thereof
WO2004020601A2 (en) * 2002-08-28 2004-03-11 University Of Florida Neurogenesis from hepatic stem cells
JP2006094701A (ja) * 2002-09-17 2006-04-13 Chugai Pharmaceut Co Ltd ７ｆ４遺伝子トランスジェニック動物
JP4897690B2 (ja) * 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
JP2008537478A (ja) * 2005-02-24 2008-09-18 ザ・スクリプス・リサーチ・インステイチユート 単離骨髄球様骨髄細胞集団及びそれを用いた治療方法
JP5250810B2 (ja) * 2006-05-31 2013-07-31 公益財団法人ヒューマンサイエンス振興財団 ユートロフィン遺伝子発現増強物質のスクリーニング
JP2008220174A (ja) * 2007-03-08 2008-09-25 Tokyoto Igaku Kenkyu Kiko 変異型βシヌクレインとαシヌクレインとを共発現する形質転換細胞及びトランスジェニック非ヒト動物
US20100310665A1 (en) 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
EP4219560A3 (en) * 2010-02-18 2023-08-23 The Regents of The University of California Integrin alpha v beta 8 neutralizing antibody
HUE058787T2 (hu) * 2010-05-05 2022-09-28 Univ New York Staphylococcus aureus leukocidinek, terápiás készítmények és azok felhasználása
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
MX343589B (es) * 2011-06-19 2016-11-11 Univ New York Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida.
CN103717234A (zh) 2011-06-19 2014-04-09 纽约大学 治疗和预防金黄色葡萄球菌感染及相关病状的方法

Also Published As

Publication number Publication date
AU2013257161B2 (en) 2017-11-09
AU2013257161A1 (en) 2014-11-20
WO2013165613A1 (en) 2013-11-07
CA2871152A1 (en) 2013-11-07
US20150132310A1 (en) 2015-05-14
JP2015517463A (ja) 2015-06-22
HK1207981A1 (en) 2016-02-19
EP2844287A4 (en) 2016-01-27
CN104428000A (zh) 2015-03-18
EP2844287A1 (en) 2015-03-11
US9657103B2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
IL258886A (en) Methods for the treatment and prevention of Staphylococcus aureus infections and related conditions
IL248959B (en) Preparations and methods for the treatment and prevention of staphylococcus aureus infections
EP2991968A4 (en) Compounds and methods of treating infections
SG11201405829WA (en) Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections
ZA201506808B (en) Antimicrobial polyamide compositions and mastitis treatment
DK2948461T3 (en) Compounds and methods for treating bacterial infections
EP3065547A4 (en) Biscationic and triscationic amphiles as antimicrobial agents
IL233605A0 (en) Compounds and methods for the treatment of Candida and Aspergillus fungi
EP2869821A4 (en) COMPOSITIONS AND METHODS FOR TREATING AND INHIBITING VIRAL INFECTIONS
IL235284A0 (en) Methods for the treatment and prevention of Staphylococcus aureus infections and related conditions
ZA201503474B (en) Compositions and methods for treating bacterial infections
IL241249A0 (en) Antisense molecules for the treatment of Staphylococcus aureus infection
IL241226A0 (en) Antisense molecules for the treatment of Staphylococcus aureus infection
PL2838903T3 (pl) Sposoby i kompozycje do leczenia zakażeń wirusowych
HK1236389A1 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
AU2013901516A0 (en) Compounds and Methods of Treating Infections
AU2013902497A0 (en) Treatment and prevention of mastitis
AU2013901517A0 (en) Methods of Treating Bacterial Infections
AU2012902449A0 (en) Novel animal infection treatment and prophylaxis
HK1215537B (en) Antimicrobial polyamide compositions and mastitis treatment
GB201212715D0 (en) Treatment of fungal infections
AU2013905016A0 (en) Treatment of animal fibres